KDR and neoplasm: Finally, combining EVT0185 with anti-PDL1 and VEGFR antibodies in the WD-CCl4 model markedly reduced tumour burden and the proportion of animals with more than 25 tumours, overcoming the limited efficacy of immunotherapy alone (Fig. 3k–m and Extended Data Fig. 6j).